CD38 is a protein found on the surface of tumor cells in MM and certain leukemias. Once attached to the CD38 site, MOR202 attracts natural killer cells that can more easily identify and eradicate the cancer cells.
MOR202 has shown encouraging results given alone, as a monotherapy, and with other therapies such as Revlimid and a proteasome inhibitor.
Other companies are interested in the CD38 area as well. Johnson & Johnson's (JNJ) biologics unit Janssen Biotech signed a licensing agreement in August with Genmab A/S worth nearly $1 billion to help develop that company's anti-CD38 biologic. Called daratumumab, the drug candidate recently received breakthrough therapy designation from the U.S. Food and Drug Administration. A Phase 1/2 safety study is ongoing.
Sanofi (SNY) also has an anti-CD38 drug candidate, SAR650984, in Phase 1 trials.Written by Pamela Taulbee
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV